![](https://investorshub.advfn.com/uicon/478509.png?cb=1505989841)
Monday, September 28, 2020 7:31:08 AM
Capital from GEM helped RLF do what it needed to do to get up on QB and I just believe that now they have cash in the coffers to roll this thing out with NeuroRX and bring us up to the Nasdaq. I don’t care that the OS went from 2.3billion to 2.8billion. If GEM wants to part with shares at .60 then that’s fine and IMO those will be absorbed quickly. Sensibly I would think GEM would like to see the SP gain traction, get over $1.00 and up-list before letting go of many. They are the largest holder and have been putting in lots of cash. Also the press states that they don’t need anymore cash beyond this to complete trials & scale RLF so I view that as a very good thing. Let’s see them stick to it.
Don’t get me wrong, I am not normally a fan of convertible deals / warrant issuance in general but these Biotechs are kinda in a different realm IMO because they can get bought out SO FAST..... I have gotten impatient before and missed the big ride on these.... I’m strapped in. Lol.
GLTYA $RLFTF
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM